APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Herpes Labialis (Oral Herpes)

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.

Selected research

Industry Growth & Trends

Global Drugs for Herpes Labialis (Oral Herpes) Industry Growth and Trends Forecast to 2032

8 January 2026113 pages

Choose your research edition.

Industry ResearchDrugs for Herpes Labialis (Oral Herpes) Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Herpes Labialis (Oral Herpes) Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Drugs for Herpes Labialis (Oral Herpes) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Herpes Labialis (Oral Herpes) Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Herpes Labialis (Oral Herpes) Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.

According to APO Research, the global Drugs for Herpes Labialis (Oral Herpes) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Drugs for Herpes Labialis (Oral Herpes) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Drugs for Herpes Labialis (Oral Herpes) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Drugs for Herpes Labialis (Oral Herpes) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Drugs for Herpes Labialis (Oral Herpes).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Drugs for Herpes Labialis (Oral Herpes) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Drugs for Herpes Labialis (Oral Herpes) Market by Company

GSK

Novartis

Teva

Mylan

Cadila

Apotex

Daewoong Pharmaceutical

Livzon

Luoxin

Med shine

Bayer (Campho Phenique)

Blistex

Kelun

Hikma

Haiwang

Carmex

Cipher

Drugs for Herpes Labialis (Oral Herpes) Segment by Type

Aciclovir

Valacyclovir

Famciclovir

Docosanol

Other

Drugs for Herpes Labialis (Oral Herpes) Segment by Application

External Use

Oral

Injection

Drugs for Herpes Labialis (Oral Herpes) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Herpes Labialis (Oral Herpes) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Herpes Labialis (Oral Herpes) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Herpes Labialis (Oral Herpes).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Drugs for Herpes Labialis (Oral Herpes) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Herpes Labialis (Oral Herpes) Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Region (2021-2026) Table 4. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Region (2027-2032) Table 6. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Type (2021-2026) Table 9. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Share Forecasted by Type (2027-2032) Table 11. North America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Application (2021-2026) Table 24. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Share Forecasted by Application (2027-2032) Table 26. North America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Drugs for Herpes Labialis (Oral Herpes) Industry Trends Table 37. Drugs for Herpes Labialis (Oral Herpes) Industry Drivers Table 38. Drugs for Herpes Labialis (Oral Herpes) Industry Opportunities and Challenges Table 39. Drugs for Herpes Labialis (Oral Herpes) Industry Restraints Table 40. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Company (2021-2026) Table 42. Global Drugs for Herpes Labialis (Oral Herpes) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Drugs for Herpes Labialis (Oral Herpes) Key Company Headquarters & Area Served Table 44. Global Drugs for Herpes Labialis (Oral Herpes) Company, Product Type & Application Table 45. Global Drugs for Herpes Labialis (Oral Herpes) Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Drugs for Herpes Labialis (Oral Herpes) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. GSK Company Information Table 49. GSK Business Overview Table 50. GSK Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. GSK Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 52. GSK Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novartis Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 57. Novartis Recent Development Table 58. Teva Company Information Table 59. Teva Business Overview Table 60. Teva Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Teva Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 62. Teva Recent Development Table 63. Mylan Company Information Table 64. Mylan Business Overview Table 65. Mylan Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Mylan Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 67. Mylan Recent Development Table 68. Cadila Company Information Table 69. Cadila Business Overview Table 70. Cadila Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Cadila Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 72. Cadila Recent Development Table 73. Apotex Company Information Table 74. Apotex Business Overview Table 75. Apotex Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Apotex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 77. Apotex Recent Development Table 78. Daewoong Pharmaceutical Company Information Table 79. Daewoong Pharmaceutical Business Overview Table 80. Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 82. Daewoong Pharmaceutical Recent Development Table 83. Livzon Company Information Table 84. Livzon Business Overview Table 85. Livzon Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Livzon Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 87. Livzon Recent Development Table 88. Luoxin Company Information Table 89. Luoxin Business Overview Table 90. Luoxin Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 92. Luoxin Recent Development Table 93. Med shine Company Information Table 94. Med shine Business Overview Table 95. Med shine Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Med shine Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 97. Med shine Recent Development Table 98. Bayer (Campho Phenique) Company Information Table 99. Bayer (Campho Phenique) Business Overview Table 100. Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 102. Bayer (Campho Phenique) Recent Development Table 103. Blistex Company Information Table 104. Blistex Business Overview Table 105. Blistex Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Blistex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 107. Blistex Recent Development Table 108. Kelun Company Information Table 109. Kelun Business Overview Table 110. Kelun Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Kelun Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 112. Kelun Recent Development Table 113. Hikma Company Information Table 114. Hikma Business Overview Table 115. Hikma Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Hikma Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 117. Hikma Recent Development Table 118. Haiwang Company Information Table 119. Haiwang Business Overview Table 120. Haiwang Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 122. Haiwang Recent Development Table 123. Carmex Company Information Table 124. Carmex Business Overview Table 125. Carmex Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Carmex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 127. Carmex Recent Development Table 128. Cipher Company Information Table 129. Cipher Business Overview Table 130. Cipher Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Cipher Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 132. Cipher Recent Development Table 133. North America Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) & (US$ Million) Table 135. North America Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2026) Table 136. North America Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. North America Drugs for Herpes Labialis (Oral Herpes) Market Share Forecast by Country (2027-2032) Table 138. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) & (US$ Million) Table 140. Europe Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2026) Table 141. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Europe Drugs for Herpes Labialis (Oral Herpes) Market Share Forecast by Country (2027-2032) Table 143. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) & (US$ Million) Table 145. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2026) Table 146. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Share Forecast by Country (2027-2032) Table 148. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) & (US$ Million) Table 150. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2026) Table 151. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Share Forecast by Country (2027-2032) Table 153. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) & (US$ Million) Table 155. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2026) Table 156. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Share Forecast by Country (2027-2032) Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Drugs for Herpes Labialis (Oral Herpes) Product Image Figure 3. Global Drugs for Herpes Labialis (Oral Herpes) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032) & (US$ Million) Figure 5. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Region: 2025 VS 2032 Figure 6. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Region (2021-2032) Figure 7. North America Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Aciclovir Image Figure 13. Global Aciclovir Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Valacyclovir Image Figure 15. Global Valacyclovir Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Famciclovir Image Figure 17. Global Famciclovir Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Docosanol Image Figure 19. Global Docosanol Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Other Image Figure 21. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Type 2025 VS 2032 Figure 24. North America Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Type (2021-2032) Figure 25. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Type (2021-2032) Figure 27. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Type (2021-2032) Figure 29. External Use Image Figure 30. Global External Use Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Oral Image Figure 32. Global Oral Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Injection Image Figure 34. Global Injection Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Application 2025 VS 2032 Figure 37. North America Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Application (2021-2032) Figure 38. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Application (2021-2032) Figure 39. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Application (2021-2032) Figure 40. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Application (2021-2032) Figure 41. Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Share by Application (2021-2032) Figure 42. Global Top 5 and 10 Drugs for Herpes Labialis (Oral Herpes) Players Market Share by Revenue in 2025 Figure 43. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 44. North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. North America Drugs for Herpes Labialis (Oral Herpes) Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. North America Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 47. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Drugs for Herpes Labialis (Oral Herpes) Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 50. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 53. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 56. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 59. Years Considered Figure 60. Research Process Figure 61. Key Executives Interviewed

Scope & coverage.

Types
  • Aciclovir
  • Valacyclovir
  • Famciclovir
  • Docosanol
  • Other
Applications
  • External Use
  • Oral
  • Injection
Companies covered
  • GSK
  • Novartis
  • Teva
  • Mylan
  • Cadila
  • Apotex
  • Daewoong Pharmaceutical
  • Livzon
  • Luoxin
  • Med shine
  • Bayer (Campho Phenique)
  • Blistex
  • Kelun
  • Hikma
  • Haiwang
  • Carmex
  • Cipher

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2021-2032)
  5. 1.4.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2021-2026)
  6. 1.4.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2027-2032)
  7. 1.5 Key Regions Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032)
  8. 1.5.1 North America Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (2021-2032)
2 Drugs for Herpes Labialis (Oral Herpes) Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Aciclovir
  3. 2.1.2 Valacyclovir
  4. 2.1.3 Famciclovir
  5. 2.1.4 Docosanol
  6. 2.1.5 Other
  7. 2.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Type
  8. 2.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Regions
  12. 2.3.1 North America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Type (2021-2026)
3 Drugs for Herpes Labialis (Oral Herpes) Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 External Use
  3. 3.1.2 Oral
  4. 3.1.3 Injection
  5. 3.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Application
  6. 3.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Regions
  10. 3.3.1 North America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Drugs for Herpes Labialis (Oral Herpes) Industry Trends
  2. 4.2 Drugs for Herpes Labialis (Oral Herpes) Industry Drivers
  3. 4.3 Drugs for Herpes Labialis (Oral Herpes) Industry Opportunities and Challenges
  4. 4.4 Drugs for Herpes Labialis (Oral Herpes) Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Drugs for Herpes Labialis (Oral Herpes) Revenue (2021-2026)
  2. 5.2 Global Drugs for Herpes Labialis (Oral Herpes) Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Drugs for Herpes Labialis (Oral Herpes) Key Company Headquarters & Area Served
  4. 5.4 Global Drugs for Herpes Labialis (Oral Herpes) Company, Product Type & Application
  5. 5.5 Global Drugs for Herpes Labialis (Oral Herpes) Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Drugs for Herpes Labialis (Oral Herpes) Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Drugs for Herpes Labialis (Oral Herpes) Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Drugs for Herpes Labialis (Oral Herpes) Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 GSK
  2. 6.1.1 GSK Company Information
  3. 6.1.2 GSK Business Overview
  4. 6.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 GSK Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  6. 6.1.5 GSK Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Teva
  14. 6.3.1 Teva Company Information
  15. 6.3.2 Teva Business Overview
  16. 6.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Teva Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  18. 6.3.5 Teva Recent Developments
  19. 6.4 Mylan
  20. 6.4.1 Mylan Company Information
  21. 6.4.2 Mylan Business Overview
  22. 6.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Mylan Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  24. 6.4.5 Mylan Recent Developments
  25. 6.5 Cadila
  26. 6.5.1 Cadila Company Information
  27. 6.5.2 Cadila Business Overview
  28. 6.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Cadila Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  30. 6.5.5 Cadila Recent Developments
  31. 6.6 Apotex
  32. 6.6.1 Apotex Company Information
  33. 6.6.2 Apotex Business Overview
  34. 6.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Apotex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  36. 6.6.5 Apotex Recent Developments
  37. 6.7 Daewoong Pharmaceutical
  38. 6.7.1 Daewoong Pharmaceutical Company Information
  39. 6.7.2 Daewoong Pharmaceutical Business Overview
  40. 6.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  42. 6.7.5 Daewoong Pharmaceutical Recent Developments
  43. 6.8 Livzon
  44. 6.8.1 Livzon Company Information
  45. 6.8.2 Livzon Business Overview
  46. 6.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Livzon Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  48. 6.8.5 Livzon Recent Developments
  49. 6.9 Luoxin
  50. 6.9.1 Luoxin Company Information
  51. 6.9.2 Luoxin Business Overview
  52. 6.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  54. 6.9.5 Luoxin Recent Developments
  55. 6.10 Med shine
  56. 6.10.1 Med shine Company Information
  57. 6.10.2 Med shine Business Overview
  58. 6.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Med shine Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  60. 6.10.5 Med shine Recent Developments
  61. 6.11 Bayer (Campho Phenique)
  62. 6.11.1 Bayer (Campho Phenique) Company Information
  63. 6.11.2 Bayer (Campho Phenique) Business Overview
  64. 6.11.3 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  66. 6.11.5 Bayer (Campho Phenique) Recent Developments
  67. 6.12 Blistex
  68. 6.12.1 Blistex Company Information
  69. 6.12.2 Blistex Business Overview
  70. 6.12.3 Blistex Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Blistex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  72. 6.12.5 Blistex Recent Developments
  73. 6.13 Kelun
  74. 6.13.1 Kelun Company Information
  75. 6.13.2 Kelun Business Overview
  76. 6.13.3 Kelun Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Kelun Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  78. 6.13.5 Kelun Recent Developments
  79. 6.14 Hikma
  80. 6.14.1 Hikma Company Information
  81. 6.14.2 Hikma Business Overview
  82. 6.14.3 Hikma Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Hikma Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  84. 6.14.5 Hikma Recent Developments
  85. 6.15 Haiwang
  86. 6.15.1 Haiwang Company Information
  87. 6.15.2 Haiwang Business Overview
  88. 6.15.3 Haiwang Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  90. 6.15.5 Haiwang Recent Developments
  91. 6.16 Carmex
  92. 6.16.1 Carmex Company Information
  93. 6.16.2 Carmex Business Overview
  94. 6.16.3 Carmex Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Carmex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  96. 6.16.5 Carmex Recent Developments
  97. 6.17 Cipher
  98. 6.17.1 Cipher Company Information
  99. 6.17.2 Cipher Business Overview
  100. 6.17.3 Cipher Drugs for Herpes Labialis (Oral Herpes) Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Cipher Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  102. 6.17.5 Cipher Recent Developments
7 North America
  1. 7.1 North America Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026)
  3. 7.3 North America Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026)
  3. 8.3 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026)
  3. 10.3 South America Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst